NEW
YORK, Aug. 6, 2024 /PRNewswire/ -- The global
liver cancer drugs market size is estimated to grow by
USD 3.28 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 10.03% during the forecast period. Increasing
incidence of liver cancer is driving market growth, with
a trend towards increasing use of monoclonal antibodies.
However, only curative option is surgical resection and
transplantation poses a challenge. Key market players include
Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol
Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka
Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead
Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR
Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co.
Ltd., Pfizer Inc., and Q BioMed Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click
for the snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Type (Immunotherapy and
Targeted therapy) and Geography (North America, Europe, Asia, and
Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Alnylam Pharmaceuticals
Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eisai
Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F.
Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui
Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc.,
Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed
Inc.
|
Key Market Trends Fueling Growth
Monoclonal antibodies are a promising approach in the treatment
of liver cancer, as traditional chemotherapy has limited
effectiveness. The main challenge in developing liver cancer drugs
is identifying tumor-specific targets. To address this, research
focuses on creating stable and high-affinity antibodies and
fragments that can target these antigens. Monoclonal antibodies
offer advantages such as sensitivity and specificity, reducing side
effects. One approved monoclonal antibody exists, with several
others in various stages of evaluation. This increasing use of
monoclonal antibodies is anticipated to fuel market growth in the
forecast period.
The Liver Cancer Drugs Market is experiencing significant growth
due to the rising number of liver cancer cases, particularly from
liver cirrhosis caused by excessive alcohol consumption, obesity,
and viral hepatitis. Immunotherapy and chemotherapeutic medications
like Sorafenib, Lenvatinib, Regorafenib, and Ramucirumab are
trending treatments for Hepatocellular Carcinoma (HCC).
Hepatectomy, liver transplantation, ablation, and radiation therapy
are also used. New drugs in the development pipeline show promise
for improving response rates. Factors driving market growth include
an aging population, increased public awareness, and the need for
novel treatments for cirrhosis and non-alcoholic steatohepatitis.
Elsevier research suggests that serum enzyme levels, body mass, and
hepatic architecture are key indicators for liver cancer screening.
Preventive measures such as viral hepatitis treatment, vaccination
programs, and safe injection practices are essential. Men and women
are equally affected, with a higher incidence in developing
countries. Genome-targeted therapy and targeted therapy are
emerging trends. The market is expected to grow despite challenges
like high costs and limited access to healthcare.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
- The liver cancer market faces significant challenges due to the
limited curative options available. The primary treatments for
liver cancer are surgical resection and transplantation. However,
these options come with their own set of challenges. Surgical
resection is the only potentially curative modality, but it can
only be performed on candidates who meet specific requirements and
is often associated with a high recurrence rate. Transplantation is
an option for patients with recurrent tumors, but the scarcity of
donor livers poses a major challenge. Moreover, the disease is
frequently diagnosed in advanced stages, making curative treatments
less feasible. As a result, there is a significant unmet need for
disease-modifying drugs that can alter tumor initiation,
growth, angiogenesis, and progression pathways. The absence of
such drugs in the market or pipeline presents a significant growth
hurdle for the liver cancer market during the forecast period.
- The Liver Cancer Drugs Market faces several challenges in
addressing the growing incidence of liver cancer. Factors such as
body mass, serum enzyme levels, and hepatic architecture can impact
the disease's diagnosis and treatment. Elsevier reports link
excess fat production, Type 2 diabetes, liver inflammation, and
cirrhosis as significant risk factors. Screening criteria for liver
cancer are essential, but challenges include identifying viral
hepatitis treatment and vaccination programs, unsafe injection
practices, and the aging population. Novel drugs in the drug
development pipeline offer hope, including genome-targeted therapy
for Hepatocellular Carcinoma (HCC), Non-Alcoholic Steatohepatitis
(NASH), and other liver cancers like Hepatoblastoma and
Intrahepatic carcinoma. Public health authorities must address
these challenges through increased public awareness, lifestyle
practices, and addressing chronic hepatitis infections like
Hepatitis B and C. The 5-year survival rate for liver cancer is
low, highlighting the need for effective treatments and improved
diagnosis. Targeted therapy, chemotherapy, and response rates are
critical areas of focus for liver cancer drugs. Men and women are
equally affected, with primary liver cancer and metastatic cancer
affecting malignant cells in liver tissues.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This liver cancer drugs market report extensively covers market
segmentation by
- Type
- 1.1 Immunotherapy
- 1.2 Targeted therapy
- Geography
- 2.1 North America
- 2.2 Europe
- 2.3 Asia
- 2.4 Rest of World (ROW)
1.1 Immunotherapy- The liver cancer drugs market is
experiencing significant growth due to the increasing prevalence of
liver cancer and the development of new, effective treatments. Key
players in the market include Roche, Bayer, and Merck. These
companies are investing in research and development to bring
innovative therapies to market, such as targeted therapies and
immunotherapies. The market is expected to continue growing, driven
by the unmet medical need for effective liver cancer treatments and
the increasing number of approved drugs.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The global gastric cancer drugs market is experiencing
significant growth due to rising incidences of gastric cancer and
advancements in targeted therapies. The market is segmented by drug
type, including chemotherapy, immunotherapy, and targeted therapy.
Major players such as Roche, Novartis, and Bristol-Myers Squibb are
driving innovation. North America
leads in market share, followed by Europe and Asia-Pacific. Increasing awareness, early
diagnosis, and improved healthcare infrastructure are key drivers.
The market is expected to continue its upward trend, offering
lucrative opportunities for industry stakeholders.
Research Analysis
Liver cancer, also known as hepatic cancer, is a malignant
growth in the liver that can be primary or metastatic. Primary
liver cancer includes various types such as hepatocellular
carcinoma (HCC), hepatoblastoma, and intrahepatic carcinoma. The
primary causes of liver cancer are chronic hepatitis infections,
particularly Hepatitis B and C, and liver cirrhosis. The 5-year
survival rate for liver cancer is relatively low, with less than
20% of patients surviving beyond five years. Public health
authorities are working to increase public awareness and promote
early diagnosis through screening programs. Novel drugs and
immunotherapy are emerging as promising treatments in the drug
development pipeline. The geriatric population and men are more
susceptible to liver cancer, and lifestyle practices such as
excessive alcohol consumption and obesity also contribute to the
risk. The intrahepatic bile duct can also be affected, leading to
bile duct cancer. The number of deaths from liver cancer continues
to rise, making it a significant global health concern. Medications
and genome-targeted therapy are being explored to improve treatment
outcomes.
Market Research Overview
Liver cancer, also known as hepatic cancer, is a malignant
growth in the liver that can be primary or metastatic. Primary
liver cancer includes hepatocellular carcinoma (HCC),
hepatoblastoma, and intrahepatic carcinoma. The five-year survival
rate for liver cancer is relatively low due to late diagnosis and
limited treatment options. Diagnosis is often challenging due to
nonspecific symptoms and lack of effective screening criteria. Risk
factors include chronic hepatitis infections, such as Hepatitis B
and C, liver cirrhosis, excess fat production leading to Type 2
diabetes, and lifestyle practices like alcohol consumption and
smoking. Public health authorities are focusing on viral hepatitis
treatment, vaccination programs, and addressing unsafe injection
practices to prevent liver cancer. Medications like Sorafenib,
Lenvatinib, Regorafenib, and Ramucirumab are used for immunotherapy
and chemotherapeutic treatments. Other treatments include
hepatectomy, liver transplantation, ablation, and radiation
therapy. The drug development pipeline includes novel drugs and
genome-targeted therapy. The aging population and gender (men more
affected than women) are also significant factors. An animal model
is used for research, along with body mass, serum enzyme levels,
and hepatic architecture. Elsevier provides comprehensive
information on liver cancer research.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Immunotherapy
- Targeted Therapy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/liver-cancer-drugs-market-size-is-set-to-grow-by-usd-3-28-billion-from-2024-2028--increasing-incidence-of-liver-cancer-to-boost-the-market-growth-technavio-302214534.html
SOURCE Technavio